Nomax Therapeutics

Metallomix builds its drug development on isotope-selective modulation of metal-dependent biology, a proprietary platform it applies first to enriched stable zinc isotopes. The platform integrates isotope chemistry, disease biology and translational pharmacology to produce stable-isotope-enriched drug candidates with defined therapeutic plans. Its work prioritizes metal-dependent pathways and disease settings where altered metal handling can be measured and mechanistically interrogated.

Its lead asset, KLS-1 (Isotozin), is an investigational isotope-enriched zinc metallodrug candidate developed first in oncology, with additional research programs exploring metabolic and neurological applications. The company differentiates on mechanism — an enriched, stable, non-radioactive zinc-64 isotope — and its lead setting is solid tumors.